Archive | clinical trial resources RSS for this section

Improving Outcomes for Canadian Children, Adolescents, and Young Adults with Cancer: A proposal for a working relationship with Health Canada [Ac2orn]

Despite gains in childhood, adolescent and young adult (CAYA) cancer research and treatment, Canadian children continue to die. Advocacy for Canadian Childhood Oncology Research Network (Ac2orn) has a plan for a coordinated Canadian effort to ensure that survival rates continue to increase, that research capacity is strengthened, and that Canada continues to lead in CAYA oncology. Our plan is supported by 30 Oncologists and 31 different cancer organizations.

Here is the link to the proposal: caya_cancer_research-Canada_health_system_efficiencies-proposal_exec_summary-jun19_2018

Advertisements

10th Annual Interaction Conference–an innovative academic-industry cancer trials meeting (Toronto, Sept 21-22, 2018)

Registration is now open!  Agenda and registration can be found at www.interaction-canada.ca. Please note new conference location below.

Interaction 2018 is an innovative Academic-Industry Cancer Trials meeting that has proved to be successful. The aim of this conference is to bring together cancer clinical trials staff from academia and industry for a two day meeting. The meeting is being organized to cater to the needs of clinical trials staff, including data coordinators, nurses, monitors, regulatory and project managers and administrators. Important goals of this meeting are to foster closer cooperation and understanding between academia and pharmaceutical company staff in the conduct of cancer studies, particularly within the Canadian perspective.

The 10th Interaction conference will be held at a new venue Vantage Venues in downtown Toronto, at 150 King St (At University Ave.), September 21-22, 2018. At this, our tenth anniversary conference, we gather together to reflect on the evolution of the field, to celebrate accomplishments, to welcome new participants to our networks, and to explore what new directions the next ten years may bring.

Please pass along to others who may be interested.  Do not hesitate to contact interactioncanada@gmail.com with any questions.

 

Stay-tuned for funding and registration information for the C17 “Next Generation of Early Phase Trials: Moving the Bar in Pediatric Oncology” educational workshop (04-Nov-2017, BC)

C17 “Next Generation of Early Phase Trials: Moving the Bar in Pediatric Oncology” educational workshop will be held on Saturday, 4 November 2017 in Vancouver, BC. The workshop is in response to the C17 DVL needs assessment that was completed last year; members from all C17 DVL sites and PROFYLE clinical site leads are encouraged to attend.

The workshop is a full day, pre-session workshop at the CCRA Canadian Cancer Research Conference. We hope that most attendees at our workshop will take the opportunity to attend the full conference as well.

The workshop will be designed to educate investigators on traditional models of early phase trials as well as newer approaches to drug development. We will also cover regulatory, ethical, advocacy and access aspects of early phase trials. The workshop will proved education, discussions, panels and time for questions.

If our fundraising is successful, our goal is to help provide some funding to C17 DVL participating centres to allow investigators and senior research staff to attend.

Registration will be live next week.

Want to celebrate Clinical Trials Day (May 20), but don’t know what to do? Read here to download a printable poster and videos from N2 and ItStartsWithMe.ca. Share at your site or on social media

  • Print out the poster below by clicking here and post it at your site this week to engage and inform patients and the public about why we celebrate Clinical Trials Day.
  • Share the “It Starts With Me” video about clinical trials through e-mail and social media, or play it on televisions in waiting rooms. This brief, 1-minute video gives individuals an overview of the potential benefits of clinical trials and information on how they can get involved. You can see the video in English here and in French here.
  • Join our “Ask Me” campaign by contacting Dawn Richards, our Business Development Specialist, at dawn.richards@n2canada.ca, and create dialogue at your site around clinical trials and how to get involved.

Happy Clinical Trials Day, and a huge thank you to all clinical research professionals for your contributions to public health and medical progress!

SAVE-THE-DATE: C17 “Next Generation of Early Phase Trials: Moving the Bar in Pediatric Oncology” educational workshop (Saturday, 4 November 2017)

C17 “Next Generation of Early Phase Trials: Moving the Bar in Pediatric Oncology educational workshop being held on Saturday, 4 November 2017 in Vancouver, BC. The workshop is in response to the C17 DVL needs assessment that was completed last year as we expanded the C17 DVL network across Canada from 8 to 11 sites. While many investigators and research staff have had experience or education in early phase trials, here was a need identified to provide education and mentorship to research staff conducting early phase trials. With the development of pediatric precision medicine trials in Canada, the need will be even greater.

The workshop is a full day, pre-session workshop at the CCRA Canadian Cancer Research Conference. We hope that most attendees at our workshop will take the opportunity to attend the full conference as well.

The workshop will be designed to educate investigators on traditional models of early phase trials as well as newer approaches to drug development. We will also cover regulatory, ethical, advocacy and access aspects of early phase trials. The workshop will proved education, discussions, panels and time for questions.

Our goal will be to help provide some funding to C17 DVL participating centres to allow investigators and senior research staff to attend.

 

More details will be circulated once available.

 

Did you know that 27 pediatric oncology studies have been added to the 3CTN portfolio since April 2014? Follow the weekly C17 Sosido Digest for our new study focus postings, like the one below.

Each pediatric hem/onc site is sent a reporting worksheet every three months.  This sheet shows all 3CTN eligible pediatric studies, or you can search the 3CTN Portfolio Directly at:  http://portfolio.3ctn.ca/

If you notice a study missing from the portfolio, please contact us.  The eligibility criteria are:

  • a cancer intervention clinical trial
  • an academic clinical trial (if a NOL is required, a non-industry organization/institute must be sponsor)
  • open at more that one Canadian site – note that the second site can be an adult oncology program

 

Release of CCTCC REB Accreditation WG Final Recommendations & Joint Response by CCTCC & Health Canada

The purpose of this message is to introduce the CCTCC REB Accreditation WG’s Final Recommendations (FRs), and the joint response by the CCTCC and Health Canada (HC) to the FRs.
The full package is available HERE.

CCTCC REB WG FRs:

There are seven FRs in total, aimed at ensuring Canada’s REB competitiveness on a global scale. FR#7, which calls for the establishment of a National Strategic Leadership Forum, is seen as the foundation of the other FRs. The FRs are based on data collected through interviews with key stakeholders in the Canadian and US REB fields as well as consultations and feedback provided by key REB stakeholders in Canada.

Background:

The CCTCC REB Accreditation WG was established in 2015, in collaboration with Health Canada, to identify strategies to improve efficiencies of ethics reviews and advance strategic issues like accreditation in regards to clinical trials. The establishment of the WG is consistent with Recommendation #4 of the Action Plant to Help Attract More Clinical Trials to Canada as well as Recommendation #3 of the Senate Report entitled “Canada’s Clinical Trials Infrastructure: A prescription for Improved Access to New Medicines”.

Given the REB centralization and harmonization initiatives that have been taking place across Canada, the WG, as stated in their Interim Report (IR), did not see formal accreditation scheme as a given. The IR’s key recommendations called for investigating the:

  • impact of these provincial initiatives
  • models of review being adopted by these initiatives,
  • standards and metrics currently being applied to REB operations (in Canada and USA)

The WG proceed with addressing the IR’s recommendations which resulted in the presented/attached FRs.

The contents of the full package include:

  1. Summary of the FRs and joint response by CCTCC and HC
  2. Full text of the FRs
  3. SPOR SHRER Report Committee recommendations – in fulfillment of FR I

CCTCC and Health Canada wish to express their profound gratitude to the members of the REB Accreditation Working Group (WG) and specifically the chair of the WG – Laurel Evans and the co-chair Karine Morine for their continued dedication and invaluable efforts in making the attached report a reality.

Please direct any questions to Elena Aminkova, Interim Director of Project Facilitation, CCTCC by emailing eaminkova@cctcc.ca

New Agents & Innovative Therapy Program December newsletter is available now

The December 2016 NAIT newsletter can be found HERE.

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at www.sickkids.ca/HaematologyOncology/nait/index.html

HELPING FAMILIES NAVIGATE:  To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and SickKids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

New Agents & Innovative Therapy Program November newsletter is available now

The November 2016 NAIT newsletter can be found HERE.

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at www.sickkids.ca/HaematologyOncology/nait/index.html

HELPING FAMILIES NAVIGATE:  To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and SickKids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

New Agents & Innovative Therapy Program October newsletter is available now

The October 2016 NAIT newsletter can be found HERE..

 

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website athttps://www.sickkids.ca/HaematologyOncology/nait/index.html

HELPING FAMILIES NAVIGATE:  To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and SickKids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.